KR20250033148A - Parp1 억제제로서의 화합물 - Google Patents

Parp1 억제제로서의 화합물 Download PDF

Info

Publication number
KR20250033148A
KR20250033148A KR1020247039613A KR20247039613A KR20250033148A KR 20250033148 A KR20250033148 A KR 20250033148A KR 1020247039613 A KR1020247039613 A KR 1020247039613A KR 20247039613 A KR20247039613 A KR 20247039613A KR 20250033148 A KR20250033148 A KR 20250033148A
Authority
KR
South Korea
Prior art keywords
group
compound
alkyl
cancer
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247039613A
Other languages
English (en)
Korean (ko)
Inventor
팅종 왕
전하이 션
에릭 피 에이 탈봇
조셉 엠 베이트먼
벤자민 에프 라헴툴라
무스타파 모로글루
태미 라두와헤티
Original Assignee
닝보 뉴베이 테크놀로지 디벨롭먼트 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닝보 뉴베이 테크놀로지 디벨롭먼트 컴퍼니 리미티드 filed Critical 닝보 뉴베이 테크놀로지 디벨롭먼트 컴퍼니 리미티드
Publication of KR20250033148A publication Critical patent/KR20250033148A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247039613A 2022-04-28 2023-02-20 Parp1 억제제로서의 화합물 Pending KR20250033148A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/089986 2022-04-28
CN2022089986 2022-04-28
PCT/CN2023/077272 WO2023207283A1 (en) 2022-04-28 2023-02-20 Compounds as parp1 inhibitiors

Publications (1)

Publication Number Publication Date
KR20250033148A true KR20250033148A (ko) 2025-03-07

Family

ID=88517229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247039613A Pending KR20250033148A (ko) 2022-04-28 2023-02-20 Parp1 억제제로서의 화합물

Country Status (6)

Country Link
US (1) US20250289814A1 (cg-RX-API-DMAC10.html)
EP (1) EP4514795A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025517106A (cg-RX-API-DMAC10.html)
KR (1) KR20250033148A (cg-RX-API-DMAC10.html)
CN (1) CN119487027A (cg-RX-API-DMAC10.html)
WO (1) WO2023207283A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
KR20260100685A (ko) * 2023-10-23 2026-06-30 길리애드 사이언시즈, 인코포레이티드 Parp1 저해제 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0906294T1 (en) * 1996-05-29 2003-04-30 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
EP1758895A1 (en) * 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
WO2009053373A1 (en) * 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2415767B1 (en) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022228387A1 (en) 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
TW202416977A (zh) 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途

Also Published As

Publication number Publication date
EP4514795A4 (en) 2025-12-31
US20250289814A1 (en) 2025-09-18
JP2025517106A (ja) 2025-06-03
EP4514795A1 (en) 2025-03-05
WO2023207283A1 (en) 2023-11-02
CN119487027A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
US11591331B2 (en) PARP1 inhibitors and uses thereof
ES2992411T3 (es) Derivados de pirazol como inhibidores de MALT1
US12421241B2 (en) Substituted pyridines as PARP1 inhibitors
JP7680619B2 (ja) Parp1阻害薬及びその使用
JP2025517106A (ja) Parp1阻害剤としての化合物
KR20210124296A (ko) 면역조절제, 조성물 및 이의 방법
KR20200011965A (ko) Map4k1의 신규한 억제제
CA2735779A1 (en) Bicyclic kinase inhibitors
US20260098024A1 (en) Parp1 inhibitors and uses thereof
JP6646044B2 (ja) キナーゼ阻害剤としての化合物および組成物
WO2023207284A1 (en) Piperazine derivatives as parp1 inhibitiors
CN110078730B (zh) 作为pi3k/mtor抑制剂的喹啉取代的稠合喹啉化合物
EP4562002A1 (en) Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
EP4367123A1 (en) Pyrimidine compounds for use as map4k1 inhibitors
AU2024369203A1 (en) Parp1 inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201